Takefumi Saito

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

Toby M. Maher, Paul Ford, Kevin M. Brown et al. · JAMA · 2023 · 127 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial

Deepali Kumar, Michael G. Ison, Jean‐Paul Mira et al. · The Lancet Infectious Diseases · 2022 · 106 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 104 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features

Akimasa Sekine, Terufumi Kato, Eri Hagiwara et al. · Lung Cancer · 2012 · 98 citations

Medicine, Oncology, Radiology +15